C
ash flow used for investing activities –14 219 –10 367 –3 852 Change in current and no
n-current financial debts 6 539 1 295 5 244 Dividends paid to shareholders of Novartis AG –3 941 –3 345 –596 Treasury share transactions
224 –473 697 Other financing cash flows –13 –50 37 Cash flow from/used for financing activities 2 809 –2 573 5 382 Cash flow from disc
ontinued o ...[+++]perations –105 105 Translation effect on cash and cash equivalents 75 –46 121 Change in cash and cash equivalents 856 –3 322 4 178 Cash and cash equivalents at January 1 2 038 5 360 –3 322 Cash and cash equivalents at December 31 2 894 2 038 856